NCT00613964

The Effects of Carperitide on Short and Long-term Prognosis in Patients With Both Cardiac and Renal Failure

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Nara Medical University · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Carperitide (alpha-human atrial natriuretic peptide) improves systemic hemodynamics in patients with heart failure through a vasodilatory action, a natriuretic action, and inhibition of the renin-angiotensin-aldosterone system and has been widely-used in Japan. However, a paucity of report is available on the effects of carperitide on short and long-term prognosis in patients with both cardiac and renal failure. The purpose of this study is to evaluate the effects of carperitide therapy on short and long-term prognosis in patients with both cardiac and renal failure, in comparison with standard therapy.

Conditions

• Heart Failure
• Renal Failure

Interventions

Type	Name	Description
DRUG	Carperitide heart failure therapy	carperitide(alpha-human atrial natriuretic peptide, 0.025-0.05μg/kg/min)
DRUG	Standard heart failure therapy	Loop diuretics, Aldosterone blockers, Beta blockers, ACE inhibitors, Angiotensin receptor blockers, Nitrates, digitalis

Timeline

• Start date: 2009-05-01
• Primary completion: 2013-05-01
• Completion: 2013-05-01
• First posted: 2008-02-13
• Last updated: 2011-07-22

Locations

1 site across 1 country: Japan